MINORITY

L.D. 1672

Date: 3-1-10 (Filing No. S-390)

HEALTH AND HUMAN SERVICES

Reproduced and distributed under the direction of the Secretary of the Senate.

STATE OF MAINE

SENATE

124TH LEGISLATURE

SECOND REGULAR SESSION

COMMITTEE AMENDMENT "A" to S.P. 644, L.D. 1672, Bill, "An Act To Require a Pharmacist To Provide Prior Notification to and Obtain Consent from the Prescribing Physician before Changing from One Formulation or Manufacturer of an Antiepileptic Drug to Another"

Amend the bill by striking out the title and substituting the following:

'An Act To Improve the Provision of Medical Care'

Amend the bill by striking out everything after the enacting clause and before the summary and inserting the following:

'**Sec. 1. 32 MRSA §13781,** as amended by PL 2007, c. 85, §§1 and 2, is further amended by adding at the end a new paragraph to read:

A pharmacist shall contact the practitioner and obtain the consent of the practitioner prior to substitution of a therapeutically equivalent drug when the practitioner has handwritten "epilepsy or seizure risk" on the prescription form. This paragraph is repealed August 1, 2012.

Sec. 2. Effective date. This Act takes effect August 1, 2010.'

SUMMARY

This amendment is the minority report of the committee. This amendment provides a new title and replaces the bill. Beginning August 1, 2010 it requires pharmacists to obtain the consent of the practitioner prescribing a prescription drug before substituting a therapeutically equivalent drug when the practitioner has handwritten on the prescription form the words "epilepsy or seizure risk." This amendment provides a repeal date of August 1, 2012.